Marie Curie Chair-Planning grant application

Reference number
Coordinator Karolinska institutet - Stockholm Brain Institute
Funding from Vinnova SEK 50 000
Project duration April 2011 - October 2011
Status Completed

Purpose and goal

The research will focus on target identification for development of therapeutic agents for HD. Dr. Becanovic is the project leader and will work with Dr. Svenningson and Dr. Tedroff, both experts in the field of HD and with Prof. Forssberg who is the director of SBI. Research will be conducted to investigate the effects of ACR-16 (Huntexil®), a promising novel treatment for HD, on pre- and post-synaptic dopamine and glutamate transmission. Further research will be conducted to evaluate the effects of ACR-16 on disease progression in transgenic animal models of HD.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2011-01465

Page statistics